The use of biomarker expression to characterize neoplastic processes

Biotechnic and Histochemistry

Volumn 72, Issue 2, 1997, Pages 96-104

  Grizzle, William E ^a   Myers, Russell B ^a   Manne, Upender ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

biomarkers; diagnosis; prognosis; surrogate end points; targets; therapy

Indexed keywords

TUMOR MARKER;

CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; HUMAN;

EID: 0030950926     PISSN: 10520295     EISSN: None     Source Type: Journal    
DOI: 10.3109/10520299709082218     Document Type: Conference Paper

References (53)

1. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A. and Lonning, P. E. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2: 811-814.
2. Arnold, M. M., Srivastava, S., Fredenburgh, J., Stockard, C. R., Myers, R. B. and Grizzle, W. E. 1996. Effects of fixation and tissue processing on immunohistochemical demonstration of specific antigens. Biotechnic & Histochemistry 71: 224-230.
3. Baretton, G. B., Diebold, J., Christoforis, G., Vogt, M., Muller, C., Dopper, K., Schneiderbanger, K., Schmidt, M. and Lohrs, U. 1996. Apotosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77: 255-264.
4. Beenken, S. W., Huang, P., Sellers, M., Peters, G., Listinsky, C., Stockard, C., Hubbard, W., Wheeler, R. and Grizzle, W. 1994. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia. J. Cell. Biochem. (Suppl.) 19: 270-277.
5. Bilim, V., Tomita, Y., Kawasaki, T., Katagiri, A., Imai, T., Takeda, M. and Takahashi, K. 1996. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J. Natl. Cancer Inst. 88: 686-688.
6. Boone, C. W. and Kelloff, G. J. 1993. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J. Cell. Biochem. (Suppl.) 17F: 37-48.
7. Boone, C. W. and Kelloff, G. J. 1994. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (Intraepithelial) neoplasia. J. Cell. Biochem. (Suppl.) 19: 10-22.
8. Boone, C. W. and Kelloff, G. J. 1995. Biomarkers of premalignant breast disease and their use as surrogate endpoints in clinical trials of chemopreventive agents. Breast 1: 228-235.
9. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Ollson, C. A., Korsmeyer, S. and Buttyan, R. 1993. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol. 143: 390-400.
10. Deshane, J., Loechel, F., Corny, R. M., Siegal, G. P., King, C. R. and Curiel, D. T. 1994. Intracellular side chain antibody directed against erbB-2 down regulates cell surface erbB-2 and exhibits a selective anti-proliferative effect in erbB-2 overexpressing cancer cell lines. Gene Therapy 1: 332-337.
11. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E. and Robert, N. 1995. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst. 87: 1254-1256.
12. Grandis, J. R., Zeng, Q. and Tweardy, D. J. 1996. Retinoic acid normalizes the increased gene transcription rate of TGFα and EGF-R in head and neck cancer cell lines. Nature Med. 2: 237-240.
13. Grizzle, W. E., Myers, R. B., Arnold M. M. and Srivastava, S. 1994. Evaluation of biomarkers in breast and prostate cancer. J. Cell. Biochem. (Suppl.) 19: 259-266.
14. Grizzle, W. E., Myers, R. B. and Oelschlager, D. K. 1995. Prognostic biomarkers in breast cancer: factors affecting immunohistochemical evaluation. Breast 1: 243-250.
15. Hasegawa, Y., Takeda, S., Ichii, S., Koizumi, K., Maruyama, M., Fujii, A., Ohta, H., Nakajima, T., Okuda, M. and Baba, S. 1995. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-speciflc amplification (MASA). Oncogene 10: 1441-1445.
16. Henriksen, R., Wilander, E. and Oberg, K. 1995. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br. J. Cancer 72: 1324-1329.
17. Joensuu, H., Pylkkanen, L. and Toikkanen, S. 1994. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145: 1191-1198.
18. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R. and Doody, L. A. 1994. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J. Cell. Biochem. (Suppl.) 19: 1-9.
19. Kyritis, A. P., Bondy, M. L., Hess, K. R., Cunningham, J. E., Zhu, D., Amos, C. J., Yung, W. K. A., Levin, V. A. and Bruner, J. M. 1995. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res. 1: 1617-1622.
20. Linn, S. C., Honkoop, A. H., Hoekman, K., van der Valk, P., Pinedo, H. M. and Giaccone, G. 1996. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br. J. Cancer 74: 63-68.
21. Lipponen, P., Pietilainen, T., Kosma, V.-M., Aaltomaa, S., Eskelinen, M. and Syrjanen, K. 1995. Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J. Pathol. 177: 49-55.
22. Manne, U., Myers, R. B., Moron, C., Srivastava, S. and Grizzle, W. E. 1996. p53 and bcl-2 protein expression in colorectal cancer. 1996 Annual Meeting, United States and Canadian Academy of Pathology. Modern Pathol. 1: 62A.
23. McDonald, T. J., Troncoso, P., Brisbay, S. M., Lagothetis, C., Chung, L. W. K., Hsieh, J.-T., Tu, S.-M. and Campbell, M. L. 1992. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen independent prostate cancer. Cancer Res. 52: 6940-6944.
24. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Russell, C. D. and LoBuglio, A. F. 1994. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J. Nuclear Med. 35: 1017-1022.
25. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C. and Barcos, M. 1994. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330: 1260-1266.
26. Myers, R. B. and Grizzle, W. E. 1996. Biomarker expression in prostatic intraepithelial neoplasia. Eur. Urol. 30: 153-166.
27. Myers, R. B., Oelschlager, D., Srivastava, S. and Grizzle, W. E. 1994a. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25: 243-248.
28. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86: 1140-1145.
29. Myers, R. B., Marshall, M. E., Oelschlager, D. K. and Grizzle, W. E. 1995. An EGF-diphtheria fusion protein kills the prostate cancer cell lines DU145 and LNCaP. Proc. Am. Assoc. Cancer Res. 36: 428.
30. erbB-2 in patients with advanced stage prostatic adenocarcinoma. Int. J. Cancer. (Pred. Oncol.) 69: 398-402.
31. erbB-2 expression in malignant prostatic cells. Proc. Am. Assoc. Cancer Res. 37: 342A.
32. Myers, R. B., Srivastava, S., Oelschlager, D. K., Brown, D. and Grizzle, W. E. 1996b. Expression of nm23-H1 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Human Pathol. 27: 1021-1024.
33. NaVone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C. and Conti, C. J. 1993. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85: 1657-1669.
34. Ofner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Totsch, M., Bocker, W., Jasani, B. and Schmid, K. W. 1995. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br. J. Cancer 72: 981-985.
35. Piris, M., Pezella, F., Martinez-Montero, J. C., Orradre, J. L., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M. A., Martinez, B., Garrido, M. C., Gatter, K., Aiello, A., Delia, D., Giardini, R. and Rilke, F. 1994. p53 and Bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Br. J. Cancer 69: 337-341.
36. Pretlow, T. P., Brasitus, T. A., Fulton, N. C., Cheyer, C. and Kaplan, E. L. 1993. K-ras mutations in putative preneoplastic lesions in human colon. J. Natl. Cancer Inst. 85: 2004-2007.
37. Pretlow, T. P., Roukhadze, E. V., O'Riordan, M. A., Chan, J. C., Amini, S. B. and Stellato, T. A. 1994. Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology 107: 1719-1725.
38. Raben, D., Buchsbaum, D. J., Khazaeli, M. B., Rosenfeld, M. E., Gillespie, G. Y., Grizzle, W. E., Liu, T. and Curiel, D. T. 1996. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Therapy 3: 567-580.
39. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Person, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M. W., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C-I., Martin, F. D., Yen, N., Xu, K., Stepehsn, L. C., McDonnell, T. J., Mukhopadhyay, T. and Cai, D. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2: 985-991.
40. Roye, G. D., Myers, R. B., Beenken, S. W. and Grizzle, W. E. 1996a. Fatty acid synthetase expression in malignant and premalignant lesions of the esophagus. Proc. Am. Assoc. Cancer Res. 37: 493A.
41. Roye, G. D., Myers, R. B., Brown, D., Poczatek, R., Beenken, S. W. and Grizzle, W. E. 1996b. CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Int. J. Cancer 69: 254-258.
42. Sainsbury, J. R., Farndon, J. R., Needham, G. K., Malcolm, A. J. and Harris, A. L. 1987. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i: 1398.
43. Shi, S., Key, M. E. and Kalra, K. L. 1991. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 39: 741-748.
44. Silvestrini, R., Veneroni, S., Daidone, M. G., Beinini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F. and Veronesi, U. 1994. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86: 499-504.
45. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, J. W., Stuart, S. G., Udove, J., Ullrich, A. and Press, F. M. 1989. Studies of the HER/neu-2 proto-oncogene in the human breast and ovarian cancer. Science 244: 707-712.
46. Smith, A. J., Stern, H. S., Penner, M., Hay, K., Mitri, A., Bapat, B. V. and Gallinger, S. 1994. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54: 5527-5530.
47. Taylor, C. R., Shi, S.-R., Chen, C., Young, L., Yang, C. and Cote, R. J. 1996. Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotechnic & Histochem. 71: 263-270.
48. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihshaus, E., Lynch, H. T., Marcus, J. N., Schwarts, L., Chen, L.-C., Mayall, B. H. and Smith H. S. 1992. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 84: 845-855.
49. Tobi, M., Luo, F. C. and Ronai, Z. 1994. Detection of K-ras mutation in colonie effluent samples from patients without evidence of colorectal carcinoma. J. Natl. Cancer Inst. 86: 1007-1010.
50. Veltri, R. W., Partin, A. W., Epstein, J. E., Marley, G. M., Miller, C. M., Singer, D. S., Patton, K. P., Criley, S. R. and Coffey, D. S. 1994. Quantitative nuclear morphometry, markovian texture descriptors and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J. Cell. Biochem. (Suppl.) 19: 249-258.
51. Volas, G. H., Leitzel, K., Teramoto, Y., Grossber, H., Demeres, L. and Lipton, A. 1996. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 78: 267-272.
52. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, W. and Galloway, D. A. 1996. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2: 72-79.
53. Yamashita, N., Minamoto, T., Ochiai, A., Onda, M. and Esumi, H. 1995. Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for Malignant progression? Cancer 75: 1527-1533.